Arrive with the Wind and Embark on a New Path —— The 2024 CSCO Academic Annual Meeting of SpaceGen Concluded Successfully!

The much-anticipated "27th National Congress of Clinical Oncology and 2024 CSCO Academic Annual Meeting" has successfully concluded in XiaMen（Fujian China）on September 29. Many experts and professors participated in the academic feast, discussing academic progress, sharing cutting-edge technologies, ideological collision and change of views. The rich and exciting contents of the meeting continuously promoted the high-quality development of clinical oncology in China.

SpaceGen presented many products and integrated application solutions for gene sequencing at the 27th National Congress of Clinical Oncology and the 2024 CSCO Annual Conference. It mainly displays star products in the field of gynecological tumor gene detection, such as "endometrial cancer molecular typing detection", "PAX1 gene methylation detection, FH/MED12 gene mutation detection". At the same time, as the co-organizer of CSCO academic special topic "Tumor Pathology Specialty: New Progress of Gynecologic Tumor Treatment and Molecular Pathology Detection", SpaceGen participated deeply and provided resource support.

01. Gathering of leading experts in the field to talk about precision medicine

As the largest and highest-level academic pageant in the field of clinical oncology in China, the theme of this congress is "taking patients as the foundation and sharing the future", focusing on the forefront of the field of tumor treatment, bringing together top experts and latest research results in the field of tumor from home and abroad, promoting academic exchanges and scientific and technological cooperation between the international and domestic fields of clinical oncology, encouraging and supporting clinical research and innovation, advocating precision oncology based on multi-disciplinary standardized comprehensive treatment, and actively promoting disciplinary development.

This annual conference attracted clinicians, research scholars, pharmaceutical enterprises and media representatives from tumor fields all over the country to gather in XiaMen to discuss the latest advances in tumor treatment, share clinical experience and stimulate innovative thinking.

02. Brilliant colors bloom in the exhibition, making a brilliant journey together.

SpaceGen has devoted herself to the cause of accurate diagnosis and treatment. Since its establishment, that company adhere to the business philosophy of "quality first, reputation first, management first, service first", relying on four core technology platform of NGS, digital PCR, fluorescent quantitative PCR and nucleic acid mass spectrometry in high-throughput sequencing, and is committed to provide overall solutions for individual accurate diagnosis of tumor.

The exhibitors at the exhibition came in droves and crowded. They stopped to watch and talked with each other. The on-site staff of SpaceGen warmly received every expert, scholar and colleague in the industry and introduced various features and application scenarios of the product in detail, which has won recognition and praise from many experts and professors. This also fully demonstrates the brand influence and comprehensive product strength of SpaceGen in the field of precision diagnosis and treatment, and heralds a new chapter in technical innovation, market expansion and customer service of SpaceGen.

Among them, a series of gynecological tumor gene detection products such as "endometrial cancer molecular typing detection", "human ctHPV16/18 quantitative detection", and "MLH1 gene methylation detection" produced by SpaceGen Co., Ltd. have been scientifically designed and fully covered, thus meeting the practical requirements for clinical practical application. With its unique innovative achievements and the firm pursuit of outstanding quality, SpaceGen has become the focus of attention.

SpaceGen Endometrial Carcinoma Molecular Classification Detection Service

Based on the RingCap? technology patented by Feishuo, the molecular typing and detection service of human endometrial cancer by SpaceGen can provide independent prognosis information of endometrial cancer, and provide reference for adjuvant treatment and conservation treatment. It contains MMR gene mutations and MSI status tests that can indicate the efficacy of immune checkpoint inhibitors and allow for screening for Lynch syndrome.

Detection content

In this study, high-throughput sequencing method was used to cover the 12 genes including Poland, TP53, MLH1, MSH2, PMS2, and MSH6, as well as MSI-related sites associated with molecular typing of endometrial carcinoma.

Detection Advantage

1. Scientific rigor: molecular typing is included in NCCN guidelines;

2. Simple and rapid: the construction of the library can be completed in only two steps by using the independent patent RingCap? technology;

3. High sensitivity: 5000× sequencing depth, with the sensitivity as high as 1%;

4. Comprehensive detection: 12 genes related to molecular typing of endometrial carcinoma and 34 MSI loci were detected at one time, with wide coverage.

It is worth mentioning that SpaceGen NGS fully automatic database integration machine also made a stunning appearance at this grand gathering. Its one-step, relaxed and efficient function attracted many exhibitors to stop and watch.

?

The SpaceGen NGS full-automatic database building all-in-one machine is a full-automatic database building system specially used for next-generation sequencing (NGS) library preparation and/or nucleic acid sample targeted enrichment, which provides 20 standard plate positions, adopts the air replacement principle to carry out 24-channel pipetting, integrates a PCR instrument module, a temperature control module, a magnetic frame module, a gripper module and an oscillation module, and can support 48 consumables required for a DNA sample database building process, does not need to manually and frequently replace the consumables, and can truly realize an unattended integrated pipetting workstation.

03. No struggle, no new moon, create an era of precision

At this annual meeting, SpaceGen not only showed its technical strength and product advantages, but also had in-depth exchanges and cooperation with many industry experts, scholars and colleagues. In the future, SpaceGen will continue to uphold the concept of "quality first, reputation foremost, management oriented, and service oriented", continuously improve its innovation ability, facilitate the development of the gene sequencing industry, and make greater contributions to the field of clinical scientific research.